| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the efficacy of a Wilms' tumor gene 1 (WT1) peptide vaccine combined with gemcitabine (GEMWT1) and compared it with gemcitabine (GEM) monotherapy for advanced pancreatic ductal adenocarcinoma (PDA) in a randomized phase II study. GEM plus the WT1 peptide vaccine prolonged progression free survival (PFS) and may improve 1-year overall survival (OS)% in patients with PDA. These clinical effects were associated with the induction of WT1-specific immune responses. Moreover, WT1 protein expression was detected in the nucleus and cytoplasm of all PDA cells. OS and disease free survival (DFS) times for patients with PDA following surgical resection demonstrated that the OS and DFS times of patients with weak cytoplasmic WT1 expression were significantly prolonged compared with those of patients with moderate-to-strong cytoplasmic WT1 expression. Therefore, the results support the development of WT1-targeted therapies to prolong survival in all patients with PDA.
|
